Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 30;12(12):1371.
doi: 10.3390/v12121371.

A Glimmer of Hope: Recent Updates and Future Challenges in Zika Vaccine Development

Priscila M S Castanha  1 , Ernesto T A Marques  1
Affiliations
Review

A Glimmer of Hope: Recent Updates and Future Challenges in Zika Vaccine Development

Priscila M S Castanha et al. Viruses. .

Abstract

The emergence and rapid spread of Zika virus (ZIKV) on a global scale as well as the establishment of a causal link between Zika infection and congenital syndrome and neurological disorders triggered unprecedented efforts towards the development of a safe and effective Zika vaccine. Multiple vaccine platforms, including purified inactivated virus, nucleic acid vaccines, live-attenuated vaccines, and viral-vectored vaccines, have advanced to human clinical trials. In this review, we discuss the recent advances in the field of Zika vaccine development and the challenges for future clinical efficacy trials. We provide a brief overview on Zika vaccine platforms in the pipeline before summarizing the vaccine candidates in clinical trials, with a focus on recent, promising results from vaccine candidates that completed phase I trials. Despite low levels of transmission during recent years, ZIKV has become endemic in the Americas and the potential of large Zika outbreaks remains real. It is important for vaccine developers to continue developing their Zika vaccines, so that a potential vaccine is ready for deployment and clinical efficacy trials when the next ZIKV outbreak occurs.

Keywords: Zika virus; clinical trials; vaccine candidates; vaccine platforms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Zika vaccine development. (A) Number of Zika vaccine candidates tested in preclinical studies using mice models and non-human primates, and in phase I and II clinical trials in humans; (B) phase I and II clinical trial sites. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Dick G.W., Kitchen S., Haddow A. Zika Virus (I). Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 1952;46:509–520. doi: 10.1016/0035-9203(52)90042-4. - DOI - PubMed
    1. Vasilakis N., Weaver S.C. Flavivirus transmission focusing on Zika. Curr. Opin. Virol. 2017;22:30–35. doi: 10.1016/j.coviro.2016.11.007. - DOI - PMC - PubMed
    1. Filipe A.R., Martins C.M.V., Rocha H. Laboratory infection with Zika virus after vaccination against yellow fever. Arch. Gesamte Virusforsch. 1973;43:315–319. doi: 10.1007/BF01556147. - DOI - PubMed
    1. Simpson D. Zika virus infection in man. Trans. R. Soc. Trop. Med. Hyg. 1964;58:335–338. doi: 10.1016/0035-9203(64)90201-9. - DOI - PubMed
    1. Kindhauser M.K., Allen T., Frank V., Santhana R.S., Dye C. Zika: The origin and spread of a mosquito-borne virus. Bull. World Health Organ. 2016;94:675–686C. doi: 10.2471/BLT.16.171082. - DOI - PMC - PubMed

Publication types

MeSH terms